WINDTREE THERAPEUTICS INC /DE/
Close on Oct 19, 2026
- Market cap
- $26.68K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2025 Ended Mar 31, 2025 | May 16, 2025 | Before market open | – | $-4.63 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 27, 2024 | During market hours | – | $-4.23 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 20, 2024 | During market hours | – | $-20.91 | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 17, 2024 | Before market open | – | $-0.95 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | During market hours | – | $-0.86 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 7, 2023 | During market hours | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | Apr 3, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 14, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 11, 2022 | During market hours | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 5, 2022 | During market hours | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 31, 2022 | Before market open | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 10, 2021 | During market hours | – | – | – |
Press releases
Announcements Windtree Therapeutics filed with the SEC
Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients
Regulation FD disclosure · EX-99.1 to Form 8-K
Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
By Email: [ ● ]
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Potential Acquisition of Titan Environmental Services, Inc.
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Windtree Therapeutics Reports First Quarter 2025
Results of operations · Listing notice · EX-99.1 to Form 8-K
Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Windtree Therapeutics Reports Year-End 2024
Results of operations · EX-99.1 to Form 8-K
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
Regulation FD disclosure · EX-99.1 to Form 8-K/A
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Windtree Therapeutics, Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Windtree Announces the Addition of Leanne Kelly
Executive or director change · Other events · EX-99.1 to Form 8-K
Windtree Announces Partnership with New Growth Advisors
Other events · EX-99.1 to Form 8-K
Windtree Therapeutics Reports Third Quarter 2024
Results of operations · Listing notice · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Windtree Announces Positive Topline Results from Its
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Windtree Therapeutics Reports Second Quarter 2024
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023
Results of operations · EX-99.1 to Form 8-K
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
Other events · EX-99.1 to Form 8-K
Windtree Therapeutics Reports Third Quarter 2023
Material agreement · Agreement terminated · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Agreement terminated · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Windtree Therapeutics Reports Second Quarter 2023
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Windtree Therapeutics Reports First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
180-day Extension to Regain Compliance
Other events · EX-99.1 to Form 8-K
Windtree Therapeutics Reports Third Quarter 2022
Results of operations · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Other events · EX-99.2 to Form 8-K
KL4 Surfactant and AEROSURF ® Global License Agreement
Material agreement · Other events · EX-99.1 to Form 8-K
Windtree Therapeutics Reports Second Quarter 2022
Results of operations · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K